Specialised AI-assisted tool used on 60,000 people works up to an hour faster than traditional scans, allowing almost half to make total return

Brainomix社とEndeavor BioMedicines社は、特発性肺線維症（IPF）治療薬タラデジブの第2a相試験ENV-IPF-101について、AI画像解析技術「Brainomix 360 e-Lung」を用いた肺構造・線維化指標の解析結果を発表した。複数の指標で治療効果が示されたと報告している。

Brainomix and Endeavor BioMedicines presented positive results on September 8, 2026, from an AI-driven quantitative analysis of CT imaging data collected in Endeavor’s Phase 2a trial of taladegib in idiopathic pulmonary fibrosis, with the findings shown at the European Respiratory Society Congress in Barcelona. According to the joint announcement, the analysis detected significant treatment effects across multiple measures of lung structure and fibrosis. The underlying study, designated ENV-IPF-101, was a randomized, double-blind, placebo-controlled 12-week trial evaluating taladegib, a hedgehog pathway inhibitor, in patients with IPF. The trial previously demonstrated that treatment with taladegib improved lung function from baseline as measured by forced vital capacity, increased total lung capacity, and reversed measures of interstitial lung disease from baseline at week 12. The E-Lung Post-Hoc Analysis Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image analysis tool that provides automatic quantifications and visualizations of radiographic features in lung CT scans. Clinicians can use these outputs to aid their diagnostic assessment of lung disease. The two companies entered into a collaboration to conduct a post-hoc analysis evaluating whether Brainomix’s AI-powered quantitative imaging outputs could support clinical trials. In the analysis of the 12-week ENV-IPF-101 trial, the companies reported that e-Lung detected significant positive...

Podcast Episode · Digital Health Section Podcast- Royal Society of Medicine · 27/10/2024 · 35m

Brainomix has been selected for the Future Fifty Scale-Up Programme, recognizing its growth and innovation in AI-powered medical imaging.

An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic pulmonary fibrosis drug taladegib.

The recent collaboration between Brainomix and Endeavor BioMedicines has reported significant positive outcomes in lung disease treatment, focusing on advanced AI imaging techniques.

Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive results from the Brainomix AI-driven quantitative analysis of HRCT imaging data in Endeavor's Phase 2a tri…

Brainomix is set to present five pivotal studies on quantitative CT in interstitial lung disease at the upcoming ERS Congress 2026 in Barcelona, Spain.

OXFORD, England and CHICAGO, Aug. 25, 2026 /PRNewswire/ -- Brainomix, a global leader in AI-powered imaging for stroke and lung disease, today announced that five abstracts showcasing its proprietary biomarkers and advanced CT analysis technologies will be presented at the European...

The Oxford-based AI medical imaging platform has raised £14 million to accelerate its commercial expansion into the US, advance its portfolio of AI-powered technology and expand its team.

ஸ்ட்ரோக் மற்றும் நுரையீரல் ஃபைப்ரோஸிஸிற்கான AI-இயங்கும் இமேஜிங் பயோமார்க்ஸர்களின் உலகளாவிய தலைவரும் முன்னோடியுமான Brainomix, இன்றைக்கு Argenica Therapeutics (ASX: AGN) உடனான அதன் கூட்டு முயற்சியின் முடிவுகளை ARG-007 ஐ மதிப்பிடும் கட்டம் II சோதனையின் மருத்துவ தரவு பகுப்பாய்வு முடிவுகளை அறிவித்தது. பிரைனோமிக்ஸ் 360 ஸ்ட்ரோக்கைப் பயன்படுத்தி பகுப்பாய்வு, எஃப்.டி.ஏ-அழிக்கப்பட்ட மற்றும் CE-குறியிடப்பட்ட AI-இமேஜிங் தளம், கடுமையான கடுமையான இஸ்கிமிக் பக்கவாதம் நோயாளிகளில் ARG-007 இன் புள்ளிவிவர ரீதியாக குறிப்பிடத்தக்க மற்றும் மருத்துவ ரீதியாக அர்த்தமுள்ள செயல்திறனை உறுதிப்படுத்தியது. பகுப்பாய்வு பக்கவாதம் மருத்துவ பரிசோதனைகளில் ஒரு அடிப்படை சவாலை நிவர்த்தி செய்தது: அடிப்படை பக்கவாதம் தீவிர மதிப்பீட்டில் மாறுபாடு.

This week’s UK tech funding deals include autonomous driving software group wave, engineering simulation company BeyondMath and more.

Brainomix, a developer of AI imaging tools for stroke and lung fibrosis, has extended its Series C round with a new £4.8m investment.

Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD), to provide objective, quantitative HRCT i…